Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes

Type 2 diabetes is among the most prevalent chronic diseases worldwide and the prevention of associated cardiovascular complications is an important treatment goal. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Chris Wai Hang, Fei, Yue, Cheung, Bernard Man Yung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2021
Materias:
Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970669/
https://www.ncbi.nlm.nih.gov/pubmed/33747548
http://dx.doi.org/10.15420/cfr.2020.19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970669/
https://www.ncbi.nlm.nih.gov/pubmed/33747548
http://dx.doi.org/10.15420/cfr.2020.19

Ejemplares similares